帕金森氏症 - KOL的見地

在本報告中，我們根據對KOL 的訪談所獲得的見解，研究和分析了帕金森氏症的治療方法，重點關注現有和正在研發的治療方法的有效性、挑戰和潛力，提供有關當前和未來治療前景的詳細資訊。

企業

目錄

摘要整理

現在與未來的治療流程

調查目的

帕金森氏症的目前治療慣行和未滿足需求

帕金森氏症治療新的方向性

已批准治療方法

• 多巴胺促效劑
• 固定用量組合藥物(FDC)
• MAO-B抑制劑
• COMT抑制劑
• 其他的藥物

開發平台治療方法

• 多巴胺促效劑
  • Aplindore(DAB 452，Seelos Therapeutics)
  • Tavapadon(AbbVie/Cerevel Therapeutics)
• FDC治療方法
  • Levodopa + carbidopa subcutaneous infusions
  • ND0612(levodopa + carbidopa subcutaneous infusion，NeuroDerm/Mitsubishi Tanabe Pharma)
  • P2B001(pramipexole + rasagiline，Pharma Two B)
• 其他的作用機制
  • Nabilone FDT(AOP Orphan Pharmaceuticals)
  • Mesdopetam(Integrative Research Laboratories)
  • Buntanetap(R-phenserine/Posiphen，Annovis Bio)
• 早期階段的醫藥品候補
  • Alpha-synuclein inhibitors
  • UCB0599(UCB)
  • PRX002(prasinezumab，Roche)
  • ENT-01(kenterin，Enterin)
  • ION464(Ionis Pharma/Biogen)
  • Radotinib(Il-Yang Pharm. Co.)
  • Repurposed drugs
  • Cell transplantation therapies
  • Viral gene delivery approaches
• 其他的作用機制/開發平台(管線)候補

未來的治療範例

附錄

Based on insights from interviews with key opinion leaders, this report provides an in depth look into the current and future treatment landscape for Parkinson's Disease, focusing on the efficacy, challenges, and potential of existing and pipeline therapies. Gain a comprehensive understanding of treatment algorithms, unmet needs, and the evolving therapeutic strategies, including the role of levodopa, emerging therapies like GLP-1 agonists, and innovative brain infusion techniques.

Key questions answered:

• What treatments currently form the backbone of Parkinson's Disease therapy?
• What are the advantages and disadvantages of these treatments?
• What are the current unmet needs and challenges in treating Parkinson's Disease?
• Which products are currently in the development pipeline, and what impact are they expected to have on treatment pathways?
• Do any of the current pipeline therapies address unmet treatment needs?
• How is the Parkinson's Disease treatment landscape expected to evolve over the next three to five years?

Key brands covered in this report:

• Alpha-synuclein inhibitors (e.g. cinpanemab, ENT-01, ION464, prasinezumab, UCB0599)
• Buntanetap ((+)(3aR)phenserine)
• Cell/gene therapies and various other early-stage MOAs
• Comtan (entacapone)
• DNL151
• Dostinex (cabergoline)
• Duopa (levodopa/carbidopa intraduodenal)
• IPX203 (carbidopa/levodopa)
• Mesdopetam
• Ongentys (opicapone)
• P2B-001 (pramipexole/rasagiline)
• PRODUODOPA/VYALEV (foscarbidopa/foslevadopa)
• Repurposed drugs (e.g. nilotinib, GLP-1 agonists (exenatide sustained-release, liraglutide, lixisenatide NLY01), etc.)
• Requip franchise (ropinirole/ER)
• Rytary (levodopa/carbidopa ER)
• Stalevo (levodopa/carbidopa/entacapone)

Companies:

Table of Contents

Executive summary

• This report is based on the leading insights from interviews with six key opinion leaders (KOLs) from the USA and six from Europe. FirstWord's research and analysis for Therapy Trends KOL Insight: Parkinson's Disease identified the following major findings:

Current and future treatment algorithm

Research objectives

Current treatment practice and unmet needs in Parkinson's disease

• Key insights summary
  • First-line treatment for PD is usually either levodopa, a dopamine agonist or a MAO-B inhibitor, depending on age, activity, severity of symptoms and formulation convenience

New directions in Parkinson's disease therapy

• Key insights summary
  • Promising new directions in PD treatment include subcutaneous levodopa, LRRK2 targeting, repurposed GLP-1 agonists and brain infusion of dopamine

Approved therapies

• Dopamine agonists
  • Key insights summary
• Fixed-dose combination (FDC) agents
  • Key insights summary
• MAO-B inhibitors
  • Key insights summary
• COMT inhibitors
  • Key insights summary
• Other agents
  • Key insights summary

Pipeline therapies

• Dopamine agonists
  • Aplindore (DAB 452; Seelos Therapeutics)
  • Tavapadon (AbbVie/Cerevel Therapeutics)
• FDC therapies
  • Levodopa + carbidopa subcutaneous infusions
  • ND0612 (levodopa + carbidopa subcutaneous infusion; NeuroDerm/Mitsubishi Tanabe Pharma)
  • P2B001 (pramipexole + rasagiline; Pharma Two B)
• Other modes of action
  • Nabilone FDT (AOP Orphan Pharmaceuticals)
  • Mesdopetam (Integrative Research Laboratories)
  • Buntanetap (R-phenserine/Posiphen; Annovis Bio)
• Early-phase drug candidates
  • Alpha-synuclein inhibitors
  • UCB0599 (UCB)
  • PRX002 (prasinezumab; Roche)
  • ENT-01 (kenterin; Enterin)
  • ION464 (Ionis Pharma/Biogen)
  • Radotinib (Il-Yang Pharm. Co.)
  • Repurposed drugs
  • Cell transplantation therapies
  • Viral gene delivery approaches
• Other mechanisms of action/pipeline candidates
  • Key insights summary

Future treatment paradigm

• Key insights summary
  • Disease modification remains elusive in PD, but the next five years should see better and earlier symptomatic treatment, together with more attention to non-motor symptoms

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe